Pazopanib Maintenance Phase II
A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia
Sponsor: Ludwig-Maximilians - University of Munich
Terminated
poor recruitment
Other terminated trials from Ludwig-Maximilians - University of Munich
- Bacterial Infections · Phase NA · Nov 2022
- Cerebral Small Vessel Diseases · Phase PHASE3 · Jul 2022
- Acute Myeloid Leukemia, Adult · Phase PHASE2 · Feb 2021
- Hyperlipoproteinemia · Phase PHASE4 · Jul 2013
- Graft Dysfunction · Phase PHASE2/PHASE3 · Jul 2013
See all terminations from Ludwig-Maximilians - University of Munich
Listed as NCT02207309, this PHASE2 trial focuses on Sarcoma and remains terminated or withdrawn. Sponsored by Ludwig-Maximilians - University of Munich, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
▶ Show 2 earlier versions
-
Jul 2017 — Dec 2017 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Jul 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ludwig-Maximilians - University of Munich
For direct contact, visit the study record on ClinicalTrials.gov .